[1]郑思越,李欣雨,廖云鹏,等.辅助生殖技术治疗费用分担机制研究[J].卫生经济研究,2024,41(11):62-66,70.
　ZHENG Siyue,LI Xinyu,LIAO Yunpeng,et al.Study on the Cost Sharing Mechanism of Assisted Reproductive Technology Treatment[J].Journal Press of Health Economics Research,2024,41(11):62-66,70.
点击复制

辅助生殖技术治疗费用分担机制研究
分享到：

卫生经济研究[ISSN:1004-7778/CN:33-1056/F]

卷:
41
期数:
2024年11期
页码:
62-66,70
栏目:
成本与费用
出版日期:
2024-10-31

文章信息/Info

Title:
Study on the Cost Sharing Mechanism of Assisted Reproductive Technology Treatment
作者:
郑思越1; 李欣雨1; 廖云鹏1; 徐 娟1; 2
1.华中科技大学同济医学院医药卫生管理学院，湖北 武汉 430030
2.华中科技大学文科双一流建设重大学科平台（医院高质量发展研究中心），湖北 武汉 430030
Author(s):
ZHENG Siyue;  LI Xinyu;  LIAO Yunpeng;  XU Juan
School of Medicine and Health Management, Tongji Medical College, Huazhong University of Science and Technology, Wuhan Hubei 430030, China
关键词:
辅助生殖技术; 治疗费用; 分担机制
Keywords:
assisted reproductive technology;  treatment cost;  cost sharing mechanism
分类号:
R19
文献标志码:
A
摘要:
当前，辅助生殖技术治疗需求不断增加，但在我国目前的多层次医疗保障体系下，尚未形成辅助生殖技术治疗费用分担机制。可借鉴德国、澳大利亚、日本辅助生殖技术治疗费用分担的实践经验：破除政策障碍，为辅助生殖技术费用保障提供合规性支持；强化政府责任，完善建立多元主体的费用共担机制；拓宽筹资渠道，形成稳定的资金来源；明确资金使用条件，控制医疗费用支出水平；采用综合控费手段，减轻患者自付费用负担。
Abstract:
At present, the demand for assisted reproductive technology treatment is increasing. However, under current multi-level medical insurance system in China, the cost sharing mechanism for assisted reproductive technology treatment has not yet been formed. Learned from the practical experiences of Germany, Australia and Japan in sharing the cost of assisted reproductive technology treatment, it is necessary to break down the policy barriers and provide compliance support for assisted reproductive technology cost protection, strengthen the responsibility of the government and improve the establishment of the cost sharing mechanism of multiple main bodies, broaden the financing channels to form a stable source of funds, clarify the conditions for the use of funds and control the level of medical expenses, and adopt comprehensive cost control measures to reduce the burden of out-of-pocket expenses on patients.

参考文献/References:

[1] 郑晓瑛，邱月.中国不孕症疾病经济负担分析[J].中国公共卫生，2012，28（03）：257-260.
[2] 国家统计局.第七次全国人口普查公报[EB/OL].（2021-05-13）[2023-07-25].https://www.gov.cn/guoqing/2021-05/13/content_56 06149.htm.
[3] Passet-Wittig J,Greil A L.Factors associated with medical help-seeking for infertility in developed countries:a narrative review of recent literature[J].Social Science & Medicine,2021,277:113782.
[4] Rauprich O,Berns E,Vollmann J.Who should pay for assisted reproductive techniques?Answers from patients, professionals and the general public in Germany[J].Human Reproduction(Oxford, England),2010,25(05):1225-1233.
[5] Peipert B J,Montoya M N,Bedrick B S,et al. Impact of in vitro fertilization state mandates for third party insurance coverage in the United States:a review and critical assessment[J].Reprod Biol Endocrinol,2022,20(01):111.
[6] Iba A,Maeda E,Jwa S C,et al.Household income and medical help-seeking for fertility problems among a representative population in Japan[J].Reprod Health,2021,18(01):165.
[7] 杨雨萌.商业健康险已覆盖7.5亿人[N].中国银行保险报，2023-05-05.
[8] 戴梦希.“试管婴儿”费用将纳入医保商业保险应如何参与生育支持[N].金融时报，2022-08-24.
[9] 黄国武.中国多层次医疗保障发展思辨：基本多层向多元多层转型[J].社会保障评论，2022，6（04）：67-82.[10] Keane M,Long J,O'Nolan G,et al.Assisted reproductive technologies:International approaches to public funding mechanisms and criteria.An evidence review[R].2017.
[11] Chambers G M,Sullivan E A, Ishihara O,et al.The economic impact of assisted reproductive technology:a review of selected developed countries[J].Fertility and Sterility,2009,91(06):2281-2294.
[12] Care A G D O.What is the Extended Medicare Safety Net (EMSN) and how does EMSN capping work?[EB/OL].(2013-08-01)[2024-02-20].https://www.adea.com.au/wp-content/uploads/2013/08/Su-mmary_of_EMSN_and_capping.pdf.
[13] 杨晶鑫，王欣昱.日本医疗保险制度的改革进程及对我国的启示[J].东北亚论坛，2010，19（01）：115-122.
[14] 乌日图.医疗保障制度国际比较研究及政策选择[D].中国社会科学院研究生院，2003.
[15] Ikegami N,Yoo B,Hashimoto H,et al.Japanese universal health coverage:evolution, achievements, and challenges[J].Lancet (London, England),2011,378(9796):1106-1115.
[16] 日本厚生劳动省.关于不孕治疗的援助[EB/OL].(2023-05-30)[2024-01-25].https://www.mhlw.go.jp/content/000901931.pdf.
[17] 任远.生育水平的影响机制和低生育率社会的生育服务支持[J].复旦学报（社会科学版），2023，65（06）：162-170.
[18] 韩优莉.医保支付方式由后付制向预付制改革对供方医疗服务行为影响的机制和发展路径[J].中国卫生政策研究，2021，14 （03）：21-27.
[19] Sauer M V.Reproduction at an advanced maternal age and maternal health[J].Fertility and Sterility,2015,103(05):1136-1143.
[20] Vander M,Wyns C. Fertility and infertility: Definition and epidemiology[J].Clinical Biochemistry,2018,62:2-10.
[21] 王雅佳.辅助生殖技术应用：伦理困境与化解之道[J].中国政法大学学报，2023（03）：112-125.
[22] 余军.生育自由的保障与规制——美国与德国宪法对中国的启示[J].武汉大学学报（哲学社会科学版），2016，69（05）：110-117.
[23] Connolly M P,Griesinger G,Ledger W,et al.The impact of introducing patient co-payments in Germany on the use of IVF and ICSI:a price-elasticity of demand assessment[J].Hum Reprod,2009,24(11):2796-2800.

相似文献/References:

[1]任杨玲,杨晓玮,沈 迟,等.陕西省不同年龄人群治疗费用分布研究——基于经常性卫生费用[J].卫生经济研究,2019,(02):46.
　REN Yang-ling,YANG Xiao-wei,SHEN Chi,et al.Study on the Distribution of Treatment Costs for Different Age Groups in Shaanxi Province——Based on Regular Health Costs[J].Journal Press of Health Economics Research,2019,(11):46.
[2]李 勇,王 冬,向国春,等.广东省恶性肿瘤治疗费用核算结果分析——基于“SHA2011”[J].卫生经济研究,2019,(09):25.
　LI Yong,WANG Dong,XIANG Guo-chun,et al.Analysis of Accounting Results of Treatment Costs for Malignant Tumors in Guangdong Province——Based on “SHA2011”[J].Journal Press of Health Economics Research,2019,(11):25.
[3]董 辉,汤质如,严 训,等.安徽省恶性肿瘤治疗费用分析——基于“卫生费用核算体系2011”[J].卫生经济研究,2021,38(2):58.
　DONG Hui,TANG Zhi-ru,YAN Xun,et al.Analysis on Malignant Tumor Treatment Cost in Anhui Province——Based on the SHA 2011[J].Journal Press of Health Economics Research,2021,38(11):58.
[4]李 涛,柴培培,张毓辉,等.我国肿瘤治疗费用核算与筹资负担分析[J].卫生经济研究,2021,38(7):17.
　LI Tao,CHAI Pei-pei,ZHANG Yu-hui,et al.Analysis of Cost Accounting and Financing Burden of Tumor Treatment in China[J].Journal Press of Health Economics Research,2021,38(11):17.
[5]陈春华,曹 勇,朱碧帆,等.2014—2018年上海市老年人治疗费用核算与分析——基于“卫生费用核算体系2011”[J].卫生经济研究,2022,39(5):27.
　CHEN Chun-hua,CAO Yong,ZHU Bi-fan,et al.Accounting and Analysis of Treatment Costs for the Elderly in Shanghai from 2014 to 2018 ——Based on "the System of Health Accounts 2011"[J].Journal Press of Health Economics Research,2022,39(11):27.
[6]王 虹,张云霞,韩 颖.县域医共体下某省基层医疗卫生机构治疗费用核算[J].卫生经济研究,2023,40(9):61.
　WANG Hong,ZHANG Yunxia,HAN Ying.Study on Treatment Costs Accounting of Primary Medical and Health Institutions under County-level Medical Community in a Certain Province[J].Journal Press of Health Economics Research,2023,40(11):61.
[7]陈荣盛,刘 平,龚亚萍,等.基于“SHA2011”的福建省女性恶性肿瘤治疗费用核算分析[J].卫生经济研究,2023,40(11):53.
　CHEN Rongsheng,LIU Ping,GONG Yaping,et al.Analysis of Treatment Costs Accounting of Female Malignant Tumors in Fujian Province based on "SHA 2011"[J].Journal Press of Health Economics Research,2023,40(11):53.
[8]刘慧玲,赵恒伯,谢志勤,等.2022年江西省罕见病治疗费用核算分析 ——基于SHA2011[J].卫生经济研究,2025,42(02):46.
　LIU Huiling,ZHAO Hengbo,XIE Zhiqin,et al.Analysis of Rare Disease Treatment Cost Accounting in Jiangxi Province in 2022 ——Based on SHA2011[J].Journal Press of Health Economics Research,2025,42(11):46.

更新日期/Last Update: 2024-10-31